Caplacizumab
drugOn this page
Also known as ALX-0081Caplacizumab yhdpCaplacizumab-yhdpCablivi
Summary
Caplacizumab (CHEMBL2109624) is an approved antibody (ATC B01AX07); indicated across 3 conditions including thrombotic disease and thrombotic thrombocytopenic purpura.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: B01AX07
- Indications: 3 conditions
- Clinical trials: 12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109624 |
| Name | Caplacizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | B01AX07 |
Also known as: ALX-0081, Caplacizumab, Caplacizumab yhdp, Caplacizumab-yhdp, Cablivi, CAPLACIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| thrombotic disease | 4 | MONDO:0000831 | HP:0004419 |
| thrombotic thrombocytopenic purpura | 4 | MONDO:0018896 | MONDO:0019740 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE3 | 3 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02553317 | PHASE3 | COMPLETED | Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura |
| NCT02878603 | PHASE3 | COMPLETED | Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) |
| NCT04074187 | PHASE2/PHASE3 | COMPLETED | A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| NCT05468320 | PHASE3 | COMPLETED | Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura |
| NCT01020383 | PHASE2 | COMPLETED | Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients |
| NCT01151423 | PHASE2 | COMPLETED | Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) |
| NCT04720261 | PHASE2 | TERMINATED | Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP |
| NCT02189733 | PHASE1 | COMPLETED | Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab. |
| NCT06358703 | Not specified | NOT_YET_RECRUITING | Impact of Acute ITTP Therapies on Long Term Neurologic and Cognitive Outcomes in ITTP Survivors |
| NCT05263193 | Not specified | COMPLETED | Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP) |
| NCT05785468 | Not specified | UNKNOWN | A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI) |
| NCT05876221 | Not specified | COMPLETED | Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).